MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

NCTID	NCT06128629 (View at clinicaltrials.gov)
Description	To evaluate the efficacy and safety of a single dose of NTLA-2001 compared to placebo in participants with ATTR-CM. (Show More)
Development Status	Active
Indication	Transthyretin Amyloidosis (ATTR) with Cardiomyopathy
Disease Ontology Term	DOID:0050638
Compound Name	NTLA-2001
Compound Alias	Nexiguran ziclumeran
Sponsor	Intellia Therapeutics
Funder Type	Industry
Recruitment Status	Active not recruiting
Enrollment Count	1200 (ESTIMATED)
Results Posted	Not Available

No.of Trial Sites	126
Locations	Singapore,United States,Czechia,Portugal,Austria,Netherlands,Sweden,Brazil,France,Argentina,Hungary,Japan,United Kingdom,Spain,New Zealand,Canada,Belgium,Norway,Taiwan,Denmark,Italy,Mexico,Israel,Australia,Germany

Has US IND	True
FDA Designations
Recent Updates	Plan to dose the first patient in the pivotal Phase 3 MAGNITUDE-2 trial for ATTRv-PN in 1Q25.